LWB.F Mesoblast Limited

Healthcare Biotechnology Frankfurt Exchange
1.16 EUR
Close of Nov 12, 2026
1.06 1.71
Market cap
EUR 1.51B
P/E
-
P/B
3.07x
ROE
-10.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is LWB.F undervalued?

Graham number

The Graham number of Mesoblast Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Mesoblast Limited fundamental analysis

No fundamental analysis for Mesoblast Limited yet.

Mesoblast Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Mesoblast Limited

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as we…

Full company profile